We are improving the lives of people suffering from mental illness and substance use disorders

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

NOVEMBER 3, 2022
Orexo Interim Report Q3 2022

OCTOBER 28, 2022
Last patient enrolled in the clinical MODIA® study 

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).

MODIA® - our digital therapy for opioid use disorder

  • to be used along with pharmaceuticals
  • 180 days treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. more than 430 patients

Orexo Social

6 December 2022

Epinephrine is the 1st-line treatment for #anaphylaxis. If you’re someone who can’t go anywhere without your auto-i… https://t.co/7oEtTBjgRp

30 November 2022

View the presentation held at @aktiespararna Stora Aktiedagen yesterday, focusing on ▶ Our core mission ▶ The comm… https://t.co/M0bwTfPSmN

29 November 2022

Today at 12-12.30 pm our CEO Nikolaj Sørensen will present @aktiespararna Stora Aktiedagen in Stockholm, Sweden. Af… https://t.co/6qbqXDJ9ZG

Financial Snapshot

Group net revenues

612.3  MSEK

LTM1

Group EBITDA

-110.6 MSEK

LTM1

US Pharma segment EBIT

304.5 MSEK

LTM1

Cash position

444 MSEK

Q3 2022

1 Last Twelve Months, Q421-Q322, for more information about financial development Link